Checkpoint cancer drug given into or near tumors
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial studies whether giving immunotherapy “checkpoint inhibitor” medicine directly into the tumor area (and/or the artery feeding it), along with a chemotherapy-style drug, can work better for advanced solid tumors. It aims to boost the immune system’s ability to attack cancer while still being safe for people with measurable tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) with cancer confirmed by biopsy/pathology, and you can likely live more than 3 months.
- You must be able to sign consent and agree to frequent visits and blood tests around treatment.
- Your liver health must be fairly preserved (Child-Pugh A or B, and not severely high score), and your “activity” on the disability scale (ECOG) must be under 2.
- Your blood and organ tests in the prior 7 days must meet minimum levels (white blood cells, hemoglobin, platelets) and acceptable clotting/liver/kidney numbers.
- You need at least one tumor spot that can be measured on scans (measurable disease).
- If you could become pregnant or cause pregnancy, you must use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
This study looks at how certain cancer drugs (called immune checkpoint inhibitors) interact with other medicines in the body. It aims to help doctors understand how to safely combine these treatments.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Hear when a new Hepatocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.